Conceptio
›
Archive
›
ClinicalTrials.gov
ClinicalTrials.gov
public full text
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
Tenet Medicines
· 2022
ClinicalTrials.gov · Datasets · License: Public Domain · 2022
Open Source ↗
minimal change disease, focal segmental glomerulosclerosis, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Trial Evaluating the Diagnostic Usefulness of Lumentin® 44 When Used as Contrast Agent
#1128334
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
#1128337
A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)
#1128333
Physical Exercise Augmented CBT for GAD
#1128335
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
#1128338
Record
· ID 804725
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.